English
ICOS/NFAT Reporter-Jurkat Recombinant Cell Line
ICOS/NFAT Reporter-Jurkat Recombinant Cell Line
Artikelnummer
BPS79668
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Screen for agonists of ICOS signaling in a physiologically relevant cellular context
Characterize T cell-mediated immune responses of ICOS and its interaction with ICOSL
Background: ICOS is a costimulatory molecule of the CD28 cell surface receptor superfamily that is expressed on activated T-cells. ICOS is involved in T-cell responses upon binding with its ligand, ICOSL (also known as B7-H2, CD275), which is normally expressed on B-cells, dendritic cells and monocytes. ICOS expression confers an activated phenotype and a strong suppressive capacity to intra-tumoral regulatory T-cells. The ICOS/ICOSL pathway is a key target for cancer immunotherapy.
Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of a chimeric receptor consisting human ICOS (also known as inducible T-cell costimulator or CD278, Genbank Accession #NM_012092) and the cytoplasmic domain of human CD3 zeta.
Format: Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Host Cell Line: Jurkat
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
Applications: Screen for agonists of ICOS signaling in a physiologically relevant cellular context
Characterize T cell-mediated immune responses of ICOS and its interaction with ICOSL
Background: ICOS is a costimulatory molecule of the CD28 cell surface receptor superfamily that is expressed on activated T-cells. ICOS is involved in T-cell responses upon binding with its ligand, ICOSL (also known as B7-H2, CD275), which is normally expressed on B-cells, dendritic cells and monocytes. ICOS expression confers an activated phenotype and a strong suppressive capacity to intra-tumoral regulatory T-cells. The ICOS/ICOSL pathway is a key target for cancer immunotherapy.
Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of a chimeric receptor consisting human ICOS (also known as inducible T-cell costimulator or CD278, Genbank Accession #NM_012092) and the cytoplasmic domain of human CD3 zeta.
Format: Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Host Cell Line: Jurkat
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
| Artikelnummer | BPS79668 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 79668 |
| Verpackungseinheit | 2 vials |
| Mengeneinheit | PAK |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
